2018
Exercise of Options – Secondary Trading Notice & Appendix 3B
26/11/2018Proteomics signs PromarkerD agreement with US big pharma
22/11/2018Change of directors’ interest notices
22/11/2018Secondary trading notice
22/11/2018Final Director’s Interest Notice
22/11/2018Appendix 3B – Issue of Director Options and Shares
22/11/2018Results of Meeting
22/11/2018Proteomics AGM Presentation
14/11/2018Adelaide Equity & Scintilla Capital appointed as advisors
09/11/2018PromarkerD kit version complete- commercial release imminent
30/10/2018Appendix 4C – September 2018 Quarterly Report
24/10/2018Diabetic kidney disease test enters Europe & Export Award
23/10/2018Proteomics Non-Executive Director Dr Dunlop to retire at AGM
23/10/2018Notice of Annual General Meeting/Proxy Form
17/10/2018Proteomics receives $834k in R&D Tax Incentive
05/10/2018Proteomics receives $928k from sale of shareholding in CPR
19/09/2018Proteomics & Atturos partner to target diagnostics in Europe
12/09/2018Proteomics to receive $928k from sale of shareholding in CPR
28/08/2018Annual Report to shareholders
28/08/2018Appendix 4E – Preliminary Final Report
28/08/2018Corporate Governance Statement and Appendix 4G
23/08/2018Diagnostics update- Pipeline yields potential new biomarkers
30/07/2018Appendix 4C – June 2018 Quarterly Report
17/07/2018Proteomics secures major contract – nears cash flow positive
21/06/2018Further information on new licence deals in USA and Mexico
18/06/2018Proteomics signs deal with Patia for PromarkerD in Mexico
28/05/2018Proteomics signs deal to launch PromarkerD test in US market
22/05/2018Appendix 3B – Issue of Employee Options
26/04/2018PIQ Quarterly Business Update
19/04/2018Europe PromarkerD patent granted for diabetic kidney disease
16/04/2018Underwriters take final $342,000 of Proteomics Options
16/04/2018Change in substantial holding
16/04/2018Change in substantial holding
16/04/2018Change in substantial holding
16/04/2018Appendix 3B
16/04/2018Secondary trading notice
06/04/2018Conversion of 90% of Proteomics Options raises of $3m
06/04/2018Secondary trading notice
06/04/2018Change of Director’s Interest Notice
06/04/2018Appendix 3B – Exercise of options
29/03/2018Change of Director’s Interest Notice
29/03/2018Secondary Trading Notice
29/03/2018Appendix 3B – Exercise of options
23/03/2018Directors Exercise PIQ Options
23/03/2018Change of Directors’ Interest Notices
23/03/2018Appendix 3B – Exercise of options
23/03/2018Secondary Trading Notice
18/03/2018Appendix 3B – Expiry of Options
14/03/2018Proteomics secures underwriting – PIQ Options to raise $3.4m
08/03/2018Secondary trading notice
08/03/2018Appendix 3B
07/03/2018Proteomics launches PromarkerD
05/03/2018Proteomics completes investment in CPR Pharma Services
05/03/2018Appendix 3B
05/03/2018Secondary trading notice
19/02/2018Expiry of Options – Letter to Option Holders
16/02/2018Appendix 4D and Interim Financial Report
15/02/2018Appendix 3B
07/02/2018Proteomics International Investor Presentation
06/02/2018Proteomics International Investor conference call
05/02/2018Proteomics International Options PIQO Exercised
05/02/2018Appendix 3B
02/02/2018Strategic alliance and investment in CPR Pharma Services
29/01/2018PromarkerD diabetic kidney disease patent granted in Japan
25/01/2018Appendix 4C – December 2017 Quarterly Report
